|Bid||170.87 x 800|
|Ask||170.95 x 1800|
|Day's range||169.39 - 172.00|
|52-week range||119.38 - 178.44|
|Beta (3Y monthly)||1.01|
|PE ratio (TTM)||22.51|
|Earnings date||5 Feb 2020 - 10 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||188.06|
LabCorp (LH) announced today that it has provided notice of its intention to redeem all of its outstanding Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) for cash on Dec. 19, 2019, (Redemption Date) in accordance with the terms of the Indenture, dated as of Oct. 23, 2006, (Indenture), between LabCorp and The Bank of New York Mellon, as trustee (Trustee) and the conversion agent. The redemption price will be equal to $966.20 per $1,000 principal amount of Zero Coupon Notes at maturity, plus accrued and unpaid contingent cash interest to the Redemption Date (Redemption Price).
LabCorp® (LH) announced today that it has priced its offering of $1,050,000,000 in senior notes. The offering consists of two tranches: $400,000,000 aggregate principal amount of 2.300% Senior Notes due 2024 (the 2024 Notes) and $650,000,000 aggregate principal amount of 2.950% Senior Notes due 2029 (the 2029 Notes and, together with the 2024 Notes, the Notes). The Notes will be senior unsecured obligations and will rank equally with LabCorp’s existing and future senior unsecured debt.
LabCorp® (LH) announced today that it has commenced a cash tender offer (the Offer) to purchase up to $300,000,000 principal amount (the Tender Cap) of its outstanding $600,000,000 aggregate principal amount of 4.625% Senior Notes due 2020 (CUSIP No. 50540RAJ1) (the Notes).
LabCorp® (LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the Notes). The Notes will be senior unsecured obligations and will rank equally with LabCorp’s existing and future senior unsecured debt. LabCorp intends to use the net proceeds of the Notes offering for general corporate purposes that may include (1) the purchase, redemption or repayment at maturity of its outstanding 2.625% Senior Notes due Feb. 1, 2020, (2) the purchase of up to $300 million aggregate purchase price of its 4.625% Senior Notes, due Nov. 15, 2020 in a concurrent tender offer, and (3) the repayment of some or all of the amounts outstanding under its term loan credit facilities.
LabCorp® (LH), a leading global life sciences company, today announced that John Ratliff is departing the company to pursue another opportunity. Dr. Brian Caveney has been named executive vice president and president of Diagnostics.
LabCorp (LH) delivered earnings and revenue surprises of 2.11% and 0.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BURLINGTON, N.C.-- -- Q3 revenue of $2.9 billion, up 3.4% over $2.8 billion last year Q3 diluted EPS of $2.25, down from $3.10 last year, which included the net gain on the disposition of the Food Solutions business of $1.22 per share Q3 adjusted EPS of $2.90, up 5.8% over $2.74 last year Q3 free cash flow of $363 million, up 136% over $154 million last year 2019 adjusted EPS guidance of $11.20 to ...
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, has completed its acquisition of the diagnostic clinical laboratory testing business of South Bend Medical Foundation (SBMF), considerably enhancing the scope of local services that LabCorp offers to hospitals, physicians, and patients across Indiana, Michigan, Ohio, and Illinois. In addition, LabCorp and SBMF will collaborate to provide integrated pathology services to customers in the region, providing an optimal combination of SBMF’s professional pathology services and LabCorp’s advanced technical capabilities, in addition to more efficient access to the leading specialty services of LabCorp’s Dianon Pathology and Integrated Oncology laboratories.
LabCorp® (LH), a leading global life sciences company, HealthEC, LLC, a 2019 Best in KLAS provider of population health management solutions, and the New Jersey Primary Care Association (NJPCA), which represents 23 community health centers throughout New Jersey, today announced the development of a database and information exchange platform supporting participating NJPCA health centers. The project will help NJPCA members achieve value-based care objectives by providing integrated lab and clinical data in a more accessible, comprehensive and secure manner, with a focus on improving outcomes for patients with chronic conditions, such as diabetes and chronic kidney disease.
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it will mark its 50th anniversary at a celebration Oct. 15 in Burlington, North Carolina, where the company has been headquartered since its founding. Dr. James B. Powell and his brothers, Dr. Thomas Edward Powell III and John Powell, founded LabCorp’s predecessor company, Biomedical Laboratories, in the former Alamance General Hospital building and tested the company’s first specimens on Oct. 6, 1969.
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
BURLINGTON, N.C.-- -- John Ratliff, current CEO of Covance, to become CEO of LabCorp Diagnostics Dr. Paul Kirchgraber, current senior vice president and head of Covance’s clinical trial testing solutions, to become CEO of Covance Both business segment CEO roles are effective Nov. 1 when Adam H. Schechter becomes president and CEO of LabCorp Judi Seltz to become chief human resources officer for LabCorp ...
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, recently published results of the largest study to date of cell-free DNA (cfDNA) screenings in multifetal pregnancies. The study, published in PLOS ONE, determined that non-invasive cfDNA screening using the MaterniT21® PLUS test offered by LabCorp’s Integrated Genetics provided reliable results that compare favorably to those for singleton pregnancies. A woman’s age-related risk for aneuploidy in most multifetal pregnancies is elevated compared to that of a woman of the same maternal age carrying a singleton pregnancy, and reliable cfDNA screening can provide valuable information to help guide care decisions.